title: Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy.
authors.affiliation: Department of Hematology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, PR China.
authors.forename: Yufeng
authors.initials: Y
authors.lastname: Li
authors.forename: Chun-Ling
authors.initials: CL
authors.lastname: Wang
authors.forename: Banhe
authors.initials: B
authors.lastname: Din
authors.forename: Liang
authors.initials: L
authors.lastname: Yu
authors.forename: Jiabin
authors.initials: J
authors.lastname: Zhu
mesh_terms: D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage* / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male
chemical_list: D000068877:Imatinib Mesylate